Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification

Int J Mol Sci. 2017 Jun 24;18(7):1350. doi: 10.3390/ijms18071350.

Abstract

Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a non-invasive biomarker in cancer. Previous studies have demonstrated increased cfDNA amount and length in different types of cancer with respect to healthy controls. The present study aims to test the hypothesis that the presence of longer DNA strands circulating in plasma can be considered a biomarker for tumor presence in thyroid cancer. We adopted a quantitative real-time PCR (qPCR) approach based on the quantification of two amplicons of different length (67 and 180 bp respectively) to evaluate the integrity index 180/67. Cell-free DNA quantity and integrity were higher in patients affected by nodular thyroid diseases than in healthy controls. Importantly, cfDNA integrity index was higher in patients with cytological diagnosis of thyroid carcinoma (Thy4/Thy5) than in subjects with benign nodules (Thy2). Therefore, cfDNA integrity index 180/67 is a suitable parameter for monitoring cfDNA fragmentation in thyroid cancer patients and a promising circulating biomarker in the diagnosis of thyroid nodules.

Keywords: cell-free DNA; integrity index; papillary thyroid carcinoma; plasma; qPCR.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor*
  • Case-Control Studies
  • Cell-Free Nucleic Acids*
  • DNA Fragmentation
  • DNA, Neoplasm*
  • Female
  • Humans
  • Liquid Biopsy
  • Male
  • Middle Aged
  • ROC Curve
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Thyroid Neoplasms / diagnosis*
  • Thyroid Neoplasms / genetics*
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / surgery
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids
  • DNA, Neoplasm